Pfizer Covid vaccine for young children may not be renewed by FDA
The move would pull the only remaining Covid vaccine for all children under five from the market.
The Moderna vaccine is only approved for children with one or more health conditions, and the pediatric Covid vaccine from Novavax is only available for children aged 12 and up with health conditions.
'It certainly would create a hole in the availability of vaccines,' said Georges Benjamin, executive director of the American Public Health Association.
'And to do it this late in the season – I think clearly it's inappropriate.'
According to an email from the National Center for Immunization and Respiratory Diseases (NCIRD), Pfizer said the FDA recently informed the pharmaceutical company that it may not renew the emergency use authorization for its pediatric Covid vaccine for the 2025 respiratory season.
The email was sent on Friday to state and local vaccination grantees.
The Pfizer vaccine is given to children between the ages of six months and four years.
Pfizer expects its Covid vaccine for children aged five to 11 to be fully licensed this fall, the email said.
The Centers for Disease Control and Prevention (CDC) is 'in discussions' with Moderna about rapidly increasing its Covid vaccine supply for young children, according to the email.
That includes internal planning about volume, timing, and potential supply gaps.
'We are working to ensure there will be sufficient supply,' said Chris Ridley, a Moderna spokesperson.
The CDC, the US Department for Health and Human Services (HHS), and Pfizer did not respond to media inquiries by publication time.
In July, Moderna received FDA approval of its Covid pediatric shot. But the vaccine was only approved for children with one or more health conditions that make them more vulnerable to Covid. This move could limit access to Covid vaccines.
'We already have a low number of people using the vaccines to start with,' Benjamin said.
'There hasn't been enough promotion of vaccinations for kids, and then you have Mr [Robert F] Kennedy's [Jr] unscientific statements about the safety and efficacy of vaccines, particularly Covid vaccines, for both pregnant women and kids. It has muddied the waters of what people know about the safety and efficacy of the vaccine.'
The vaccine is extremely effective, especially against hospitalization and death.
Yet only 5.6% of children aged six months to four years are vaccinated against Covid, and about 15% of children aged five to 17 are vaccinated, according to the CDC.
While older adults have the highest rates of hospitalization and death, children continue seeing hospitalization rates from Covid similar to rates in 2020 and 2021.
And there are other concerns with Covid infection.
'We don't know the long-term impact for kids who have gotten Covid as a disease. We do know it does cause a multi-systemic inflammatory process in a number of kids, which is very severe, and we don't know the long-term implications for long Covid in kids,' Benjamin said.
Covid cases are rising in many parts of the US amid other vaccine restrictions proposed and implemented by health officials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
25 minutes ago
- Daily Mail
US records more cases of virus prompting Covid-era restrictions in China... as travel warnings take effect
Cases of the debilitating chikungunya virus sweeping through China are also surging in the US, health officials have warned. CDC officials have reported four more cases this week, bringing the total to 50 cases of chikungunya in the US, all of which are in people who traveled to areas where it is more common like Asia and South America. It is unclear how many are linked to China's outbreak. The virus, which is spread by the Aedes mosquito, can cause sudden, agonizing joint pain in the hands and feet that can be so severe that it leaves sufferers unable to move normally for months. Chikungunya is tearing through China with more than 10,000 cases, leaving the nation battling its largest outbreak ever. The outbreak has prompted the CDC to issue a level 2 travel warning for China, which urges Americans to take extra precautions when visiting the area. The notice also applies to Brazil, Colombia, India, Mexico, Nigeria, Pakistan, the Philippines and Thailand. Chikungunya is a 'nationally notifiable' condition in the US, meaning health authorities can voluntarily report cases to the agency for national tracking and monitoring. While a handful of cases pop up in the US every year from people traveling to high-risk areas, it hasn't experienced local transmission since 2019. But with 1.6million people traveling between the US and China every year, mosquitoes in America could bite an infected traveler and begin transmitting the virus locally to Americans. Dr Louisa Messenger, a mosquito researcher in Nevada, previously told 'This outbreak in China is very concerning. It [the virus] could already be here in the US; and really it's just one plane flight away.' Along with the CDC, travel agencies and cruise lines have also issued warnings about preventing mosquito-borne diseases, including chikungunya, dengue and Lyme disease, all of which have been detected in the US so far this year. Last month, Norwegian Cruise Line warned guests traveling to Italy this year to use insect repellent and wear clothing treated with permethrin, which can repel ticks and mosquitoes. Aedes mosquitoes are common in Italy, especially around coastal areas. Authorities in Italy reported the first locally acquired cases of both dengue and chikungunya, prompting the warnings from Norwegian Cruise Line. The Massachusetts Department of Health also urged in a recent health bulletin not to travel to areas with known outbreaks of mosquito-borne illnesses and get necessary vaccines if you are traveling to these areas. Health officials in New Jersey also stated: 'The best way to prevent chikungunya is to prevent mosquito bites and avoid travel to areas with ongoing chikungunya outbreaks.' Chikungunya is spread to humans from a bite from the Aedes mosquito, which also spread dengue fever, yellow fever and Zika virus. The infection does not spread from person to person through bodily contact or saliva. However, pregnant women who become infected near the time of delivery can pass the virus to their baby during birth, which can result in severe illness in the newborn. About 15 to 35 percent of people infected with the virus are asymptomatic, the CDC reports. The incubation period is typically three to seven days and the most common symptom is a sudden onset of a fever over 102 degrees Fahrenheit (39 degrees Celsius). Other symptoms of chikungunya virus include headache, nausea, rash, muscle aches, swelling and redness of the conjunctiva (the white part of the eye and inner eyelids) and joint pain that is sometimes severe and debilitating in the hands or feet. In severe cases, life-threatening complications involving the heart and brain can occur such as inflammation, irregular heartbeats and organ failure. Symptoms usually last seven to 10 days, but patients may experience lifelong complications such as persistent joint pain. There is no specific treatment for chikungunya, and doctors mostly focus on easing symptoms like over-the-counter pain and fever medications. However, there are two vaccines available for people visiting an area with an outbreak. China has recorded approximately 10,000 chikungunya viruses this year, making this its largest outbreak of the virus. Mitigation efforts, including using drones to spray insecticide in mosquito-infested areas has led to a slow down in new cases, though more than 1,000 were still recorded in the last week. According to the CDC, chikungunya was rarely detected in American travelers before 2006. But between 2006 and 2013, the US logged around 30 imported cases a year, all in people who had recently visited affected regions in Asia, Africa or the Indian Ocean. In 2014, a total of 2,799 cases were reported - including 12 that were locally acquired - in states and territories such as Florida, Texas, Puerto Rico and the US Virgin Islands, making it the country's worst year on record for the virus.
Sky News
2 hours ago
- Sky News
AI used to design antibiotics that can combat drug-resistant superbugs gonorrhoea and MRSA
Why you can trust Sky News New antibiotics that could kill drug-resistant gonorrhoea and MRSA have been developed with the help of artificial intelligence (AI), researchers have said. A team at Massachusetts Institute of Technology (MIT) used generative AI algorithms to design more than 36 million possible compounds. Once computationally screened for antimicrobial properties, the top candidates were shown to be structurally different from any existing antibiotics. They also seemed to work in a new way - by disrupting bacterial cell membranes. Antibiotics kill bacteria, but some infections have become resistant to drugs. It is estimated that drug-resistant bacterial infections cause nearly 5 million deaths per year worldwide. Two compounds were found to be effective against gonorrhoea and MRSA infections - namely NG1 and DN1 respectively. A non-profit organisation is now working on modifying the compounds to make them suitable for further testing. The research appeared on Thursday in scientific journal Cell. MIT Professor James Collins, the paper's senior author, said: "We're excited about the new possibilities that this project opens up for antibiotics development. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible." This could re-energise the drug pipeline just in time Could AI save us from the antibiotic apocalypse? That's the hope from new research in which scientists designed novel drugs atom-by-atom to beat two notorious superbugs, including MRSA. Antibiotic resistance is a growing problem, causing the deaths of around 5 million people a year. Even routine operations could become life-threatening events in future - unless a new generation of antibiotics can be found. Enter the data crunching power of artificial intelligence. Researchers at the Massachusetts Institute of Technology used generative AI to design millions of possible compounds that don't exist or haven't yet been discovered by science - and then screened them for likely activity against bacteria, as well as toxicity in human cells. The top candidates were structurally unlike any existing antibiotics and appeared to work in completely novel ways to disrupt the membranes of bacterial cells. Tests on bacteria in lab dishes and infected mice identified two possible antibiotics against MRSA and the bacteria that causes gonorrhoea. There would be many years of further testing, including clinical trials, before the drugs would be prescribed by doctors. But the new approach could prove significant. The last major class of antibiotics was discovered in the 1980s. There have been tweaks to the drugs since, but that only slowed the development of resistance. Many pharmaceutical companies have given up on antibiotic development, daunted by the challenge and the cost. Using AI could take out some of the risk of failure. And that might re-energise the drug pipeline just in time. One of the study's lead authors, MIT postdoc Aarti Krishnan, said: "We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way.
Reuters
2 hours ago
- Reuters
US health department reinstates task force on safer childhood vaccines
Aug 14 (Reuters) - The U.S. Department of Health and Human Services said on Thursday it is reinstating its task force on a federal panel for safer childhood vaccines after 27 years. The panel was created by Congress to improve the safety, quality and oversight of vaccines administered to American children. The original task force was disbanded in 1998, said the health agency, adding that National Institutes of Health director Jay Bhattacharya will serve as chairman of the task force. The task force will work closely with the Advisory Commission on Childhood Vaccines, the HHS said.
